2020
FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C
So-Armah KA, Lim JK, Re V, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS, Team V. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress In Cardiovascular Diseases 2020, 63: 184-191. PMID: 32068085, PMCID: PMC7278895, DOI: 10.1016/j.pcad.2020.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsFemaleHealth StatusHeart FailureHepatitis CHIV InfectionsHIV Long-Term SurvivorsHumansIncidenceLiver CirrhosisMaleMiddle AgedPrognosisRisk AssessmentRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsUnited StatesVentricular Function, LeftVeterans HealthViral LoadConceptsType of HFIncident heart failureHeart failureHepatitis C statusAdvanced fibrosisLiver fibrosisEjection fractionHazard ratioC statusVeterans Aging Cohort StudyRisk of HFpEFLast clinic visitReduced ejection fractionAging Cohort StudyLiver fibrosis scoresPrevalent cardiovascular diseaseFirst HF eventProportional hazards modelIncident HFpEFHepatitis CClinic visitsCohort studyPrimary outcomeFibrosis scoreHF events
2017
Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study
Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Vasan RS, Oursler KA, Gottdiener J, Gottlieb S, Leaf D, Rodriguez-Barradas M, Tracy RP, Gibert CL, Rimland D, Bedimo RJ, Brown ST, Goetz MB, Warner A, Crothers K, Tindle HA, Alcorn C, Bachmann JM, Justice AC, Butt AA. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiology 2017, 2: 536-546. PMID: 28384660, PMCID: PMC5541383, DOI: 10.1001/jamacardio.2017.0264.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCase-Control StudiesCD4 Lymphocyte CountCohort StudiesFemaleHeart FailureHIV InfectionsHumansMaleMiddle AgedProportional Hazards ModelsRisk AssessmentRisk FactorsRisk Reduction BehaviorStroke VolumeUnited StatesUnited States Department of Veterans AffairsVeteransViral LoadConceptsRisk of HFrEFHuman immunodeficiency virus (HIV) infectionVeterans Aging Cohort StudyAntiretroviral therapy eraRisk of HFpEFReduced ejection fractionCells/mm3Immunodeficiency virus infectionHeart failureAging Cohort StudyHIV infectionEjection fractionUninfected veteransTherapy eraCohort studyVirus infectionHIV-1 RNA viral loadTime-updated CD4 cell countHIV-specific factorsBaseline cardiovascular diseaseCD4 cell countRNA viral loadCopies/mLRace/ethnicityObservational cohort